<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Felix</title>
    <link>https://old.felixonline.co.uk/authors/peter_green/</link>
    <description>Recent content on Felix</description>
    <atom:link href="https://old.felixonline.co.uk/authors/peter_green/" rel="self" type="application/rss+xml" />
    
      <item>
        <title>From bad to worse for Puma Biotechnology</title>
        <link>https://old.felixonline.co.uk/articles/2019-04-28-from-bad-to-worse-for-puma-biotechnology/</link>
        <pubDate>Fri, 09 Nov 2018 17:00:00 +0000</pubDate>
        
          <author>Peter Green,</author>
        
        <guid>https://old.felixonline.co.uk/articles/2019-04-28-from-bad-to-worse-for-puma-biotechnology/</guid>
        <description>If you want a good example of how volatile biotechnology stocks can be, look no further than Puma Biotechnology Inc. This cancer-focused biotechnology company was founded 8 years ago and went public in 2012 with shares trading around $10 per share. In 2014 that share price rocketed to +$260 â€¦</description>
      </item>
    
  </channel>
</rss>
